AB 753

This bill creates a new separate nonlapsible trust fund designated as the

medicinal psilocybin treatment fund and establishes a pilot program to study the

effects of medicinal psilocybin treatment on patients with post-traumatic stress

syndrome (PTSD).

The medicinal psilocybin treatment pilot program created by this bill must be

established by the Board of Regents of the University of Wisconsin System at the

University of Wisconsin-Madison in collaboration with that institution's

Transdisciplinary Center for Research in Psychoactive Substances and its School of

Pharmacy. The individuals eligible to participate in the pilot program must be

veterans who are 21 years of age or older and who suffer from treatment-resistant

PTSD. Individuals who are law enforcement officers are not eligible to participate

in the pilot program study. The psilocybin therapy provided by the pilot program

must be provided through pathways approved by the federal Food and Drug

Administration, and the research accomplished in the pilot program may be

accomplished in conjunction with other medications approved by the federal Food

and Drug Administration. The board must ensure that no health information

disclosed in the course of conducting the program contains personally identifiable

information. The researchers conducting the program must create reports for the

governor and the appropriate standing committees of the legislature regarding

progress of the pilot program and the studies conducted as part of the program.

The medicinal psilocybin treatment fund created in this bill consists of

donations, gifts, grants, bequests, moneys transferred from the general fund, and all

earnings and other investment income of the fund. This trust fund is managed by

the State of Wisconsin Investment Board. Moneys in the fund may be expended for

the purpose for which any donation, gift, grant, or bequest is made and for the

administration of the pilot program.